PSG Stock Overview
Manufactures and sells over-the-counter drugs and other healthcare products in Germany.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
PharmaSGP Holding SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €20.20 |
52 Week High | €27.60 |
52 Week Low | €17.70 |
Beta | 0.019 |
11 Month Change | -12.93% |
3 Month Change | -13.68% |
1 Year Change | -25.74% |
33 Year Change | -14.41% |
5 Year Change | n/a |
Change since IPO | -41.45% |
Recent News & Updates
Recent updates
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings
May 06Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio
Mar 02PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04Shareholder Returns
PSG | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -6.5% | 6.7% | -0.5% |
1Y | -25.7% | -19.1% | -0.3% |
Return vs Industry: PSG underperformed the German Pharmaceuticals industry which returned -20.8% over the past year.
Return vs Market: PSG underperformed the German Market which returned -0% over the past year.
Price Volatility
PSG volatility | |
---|---|
PSG Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 4.4% |
Market Average Movement | 4.6% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PSG has not had significant price volatility in the past 3 months.
Volatility Over Time: PSG's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 89 | Natalie Weigand | pharmasgp.com |
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
PSG fundamental statistics | |
---|---|
Market cap | €242.20m |
Earnings (TTM) | €18.11m |
Revenue (TTM) | €107.29m |
13.4x
P/E Ratio2.3x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PSG income statement (TTM) | |
---|---|
Revenue | €107.29m |
Cost of Revenue | €9.74m |
Gross Profit | €97.56m |
Other Expenses | €79.45m |
Earnings | €18.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.51 |
Gross Margin | 90.93% |
Net Profit Margin | 16.88% |
Debt/Equity Ratio | 163.9% |
How did PSG perform over the long term?
See historical performance and comparison